Particle.news

Oral Wegovy Sustains Weight Loss After Switch From Injectables

The real-world results strengthen Novo Nordisk's bid to win back market share from Eli Lilly.

Overview

  • Data presented at the European Association for the Study of Diabetes in Milan on Wednesday show patients who switched from weekly injectable GLP-1 treatments to daily oral semaglutide continued to lose weight.
  • In an observational dataset of 194 patients compiled with telehealth provider Ro, mean weight fell 4.1% (about 4.0 kg) over three months and the share classified as clinically obese dropped from 87.1% to 65.5%.
  • Nearly 41% of participants lost at least 5% of their body weight, but the study relied partly on patient self-reports and its design does not establish the causal proof of randomized trials.
  • Novo has launched the Wegovy pill in the US, UK, Germany and the UAE and company presentations this month say oral formulations now make up roughly one-third of US obesity prescriptions with Novo capturing more than 80% of new oral starts.
  • Executives say the pill could help reverse Novo's market setbacks after losing sales leadership to Eli Lilly and point to a large global anti-obesity market that analysts estimate could reach or exceed $100 billion a year by the end of the decade.